Esomeprazole tablet vs omeprazole capsule in treating erosive esophagitis

World Journal of Gastroenterology

Volumn 11, Issue 20, 2005, Pages 3112-3117

  Chen, Chih Yen ^a   Lu, Ching Liang ^a   Luo, Jiing Chyuan ^a   Chang, Full Young ^a   Lee, Shou Dong ^a   Lai, Yung Ling ^b  

^a NATIONAL YANG MING UNIVERSITY   (Taiwan)

^b ASTRAZENECA   (United Kingdom)

Author keywords

Esomeprazole; Esophagitis; Someprazole

Indexed keywords

ESOMEPRAZOLE; OMEPRAZOLE;

ADULT; AGED; ARTICLE; CELLULITIS; CHINESE; CLINICAL ARTICLE; CLINICAL FEATURE; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG CAPSULE; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRY SKIN; FEMALE; HEADACHE; HEALING; HEARTBURN; HUMAN; MALE; RANDOMIZED CONTROLLED TRIAL; REFLUX ESOPHAGITIS; REMISSION; SCORING SYSTEM; SOMNOLENCE; TABLET FORMULATION; TREATMENT OUTCOME;

EID: 20344380722     PISSN: 10079327     EISSN: None     Source Type: Journal    
DOI: 10.3748/wjg.v11.i20.3112     Document Type: Article

References (40)

1. Dodds WJ, Hogan WJ, Heim JF, Dent J. Pathogenesis of reflux esophagitis. Gastroenterology 1981; 81: 376-394
2. Dent J, Brum J, Fendrick AM, Fennerty MB, Janssens J, Kahrilas PJ, Lauritsen K, Reynolds JC, Shaw M, Talley NJ. An evidence-based appraisal of reflux disease management-the Genval workshop report. Gut 1999; 44 (Suppl 2): S1-S16
3. Tytgat GN, Nio CY. The medical therapy of reflux esophagitis. Baillieres Clin Gastroenterol 1987; 1: 791-807
4. Bell N, Hunt RH. Role of gastric acid suppression in the treatment of gastro-esophageal reflux disease. Gut 1992; 33: 118-124
5. Bate CM, Green JR, Axon AT, Murray FE, Tildesley G, Emmas CE, Taylor MD. Omeprazole is more effective than cimetidine for the relief of all grades of gastroesophgeal reflux disease-associated heartburn, irrespective of the presence or absence of endoscoic esophagitis. Aliment Pharmacol Ther 1997; 11: 755-763
6. Galmiche JP, Barthelemy P, Hamelin B. Treating the symptoms of gastroesophageal reflux disease: A double-blind comparison of omeprazole and cisapride. Aliment Pharmacol Ther 1997; 11: 765-773
7. Hallerback B, Unge P, Carling L, Edwin B, Glise H, Havu N, Lyrenas E, Lundberg K. Omeprazole or ranitidine in long-term treatment of reflux esophagitis. The Scandinavian Clinics for United Research Group. Gastroenterology 1994; 107: 1305-1311
8. Lu CL, Chen TS, Chen CY, Chang FY, Kang LJ, Lee SD. Treatment of erosive oesophagitis with omeprazole: A comparison with different delivery system. Digest Liver Dis 2001; 33: 731
9. Lindberg P, Keeling D, Fryklund J, Andersson T, Lundborg P, Carlsson E. Review article: Esomeprazole-enhanced bioavailability, specificity for the proton pump and inhibition of acid secretion. Aliment Pharmacol Ther 2003; 17: 481-488
10. Sjovall H, Bjornsson E, Holmberg J, Hasselgren G, Rohss K, Hassan-Alin M. Pharmacokinetic study of esomeprazole in patients with hepatic impairment. Eur J Gastroenterol Hepatol 2002; 14: 491-496
11. Investigator's brochure on esomeprazole for oral use. 1999
12. Lind T, Rydberg L, Kyleback A, Jonsson A, Andersson T, Hasselgren G, Hoimberg J, Rohss K. Esomeprazole provides improved acid control vs omeprazole in patients with symptoms of gastro-oesophageal reflux disease. Aliment Pharmacol Ther 2000; 14: 861-867
13. Andersson T, Hassan-Alin M, Hasselgren G, Rohss K, Weidolf L. Pharmacokinetic studies with esomeprazole, the (S)-isomer of omeprazole. Clin Pharmacokinet 2001; 40: 411-426
14. Kahrilas PJ, Falk GW, Johnson DA, Schmitt C, Collins DW, Whipple J, D'amico DD, Hamelin B, Joelsson B. Esomeprazole improves healing and symptom resolution as compared with omeprazole in reflux oesophagitis patients: A randomized controlled trial. Aliment Pharmacol Ther 2000; 14: 1249-1258
15. Chang CS, Poon SK, Lien HC, Chen GH. The incidence of reflux esophagitis among the Chinese. Am J Gastroenterol 1997; 92: 668-671
16. Goh KL, Chang CS, Fock KM, Ke M, Park HJ, Lsm SK. Gastroesophageal reflux disease in Asia. J Gastroenterol Hepatol 2000; 15: 230-238
17. Kao AW, Sheu BS, Sheu MJ, Chang YM, Huang SF, Chuang CH, Lai YL, Kao YH. On-demand therapy for Los Angeles grades A and B reflux esophagitis: Esomeprazole versus omeprazole. J Formos Med Assoc 2003; 102: 607-612
18. Armstrong D, Bennett JR, Blum AL, Dent J, De Dombal TF, Galmiche JP, Lundell L, Margulies M, Richter JE, Spechler SJ, Tytgat GN, Wallin L. The endoscopic assessment of esophagitis: A progress report on observer agreement. Gastroenterology 1996; 111: 85-92
19. Jankowski JA, Provenzale D, Moayyedi P. Esophageal adenocarcinoma arising from Barrett's metaplasia has regional variations in the west. Gastroenterology 2002; 122: 588-590
20. Jankowski JA, Harrison RF, Perry I, Balkwill F, Tselepis C. Barrett's metaplasia. Lancet 2000; 356: 2079-2085
21. Whittles CE, Biddlestone LR, Burton A, Barr H, Jankowski JA, Warner PJ, Shepherd NA. Apoptotic and proliferative activity in the neoplastic progression of Barrett's oesophagus: A comparative study. J Pathol 1999; 187: 535-540
22. Richter JE. Gastroesophageal reflux disease in the older patient: Presentation, treatment, and complications. Am J Gastroenterol 2000; 95: 368-373
23. Dent J. Gastro-oesophageal reflux disease. Digestion 1998; 59: 433-445
24. Pope CE II. Acid-reflux disorders. N Eng J Med 1994; 331: 656-660
25. Castell DO, Kahrilas PJ, Richter JE, Vakil NB, Johnson DA, Zuckerman S, Skammer W, Levine JG. Esomeprazole (40 mg) compared with lansoprazole (30 mg) in the treatment of erosive esophagitis. Am J Gastroenterol 2002; 97: 575-583
26. Lauritsen K, Deviere J, Bigard MA, Bayerdorffer E, Mozsik G, Murray F, Kristjansdottir S, Savarino V, Vetvik K, De Freitas D, Orive V, Rodrigo L, Fried M, Morris J, Schneider H, Eklund S, Larko A. Esomeprazole 20 mg and lansoprazole 15 mg in maintaining healed reflux oesophagitis: Metropole study results. Aliment Pharmacol Ther 2003; 17: 333-341
27. Vakil NB, Shaker R, Johnson DA, Kovacs T, Baerg RD, Hwang C, D'Amico D, Hamelin B. The new proton pump inhibitor esomeprazole is effective as a maintenance therapy in GERD patients with healed erosive oesophagitis: A 6-mo, randomized, double-blind, placebo-controlled study of efficacy and safety. Aliment Pharmacol Ther 2001; 15: 927-935
28. Gough AL, Long RG, Cooper BT, Fosters CS, Garrett AD, Langworthy CH. Lansoprazole versus ranitidine in the maintenance treatment of reflux esophagitis. Aliment Pharmacol Ther 1996; 10: 529-539
29. Hatlebakk JG, Berstad A, Carling L, Svedberg LE, Unge P, Ekstrom P, Halvorsen L, Stallemo A, Hovdenak N, Trondstad R. Lansoprazole versus omeprazole in short-term treatment of reflux esophagitis. Results of a Scandinavian multicentre trial. Scand J Gastroenterol 1993; 28: 224-228
30. Castell DO, Richter JE, Robinson M, Sontag SJ, Haber MM. Efficacy and safety of lansoprazole in the treatment of erosive reflux esophagitis. The Lansoprazole Group. Am J Gastroenterol 1996; 91: 1749-1757
31. Mee AS, Rowley JL. Rapid symptom relief in reflux esophagitis: A comparison of lansoprazole and omeprazole. Aliment Pharmacol Ther 1996; 10: 757-763
32. Robinson M, Sahba B, Avner D, Jhala N, Greski-Rose PA, Jennings DE. A comparison of lansoprazole and ranitidine in the treatment of erosive esophagitis. Multicentre Investigational Group. Aliment Pharmacol Ther 1995; 9: 25-31
33. Mössner J, Hölscher AH, Herz R, Schneider A. A double-blind study of pantoprazole and omeprazole in the treatment of reflux esophagitis: A multicenter trial. Aliment Pharmacol Ther 1995; 9: 321-326
34. Xia HH, Talley NJ. Helicobacter pylori infection, reflux esophagitis, and atrophic gastritis: An unexplored triangle. Am J Gastroenterol 1998; 93: 394-400
35. Bercík P, Verdú EF, Armstrong D. H pylori related increase in omeprazole (ome) effect is associated with ammonia production (abstr). Gastroenterology 1996; 110: A64
36. Endo M, Sugihara K. Long-term maintenance treatment of reflux esophagitis resistant to H2-RA with PPI (lansoprazole). Nippon Rinsho 2000; 58: 1865-1870
37. Umeda N, Miki K, Hoshino E. Lansoprazole versus famotidine in symptomatic reflux esophagitis: A randomized, multicenter study. J Clin Gastroenterol 1995; 20 (Suppl 1): S17-S23
38. Talley N. Managing reflux disease-Critically reviewing the evidence in 2003. International Symposium, Marbella, Spain, January 18, 2003
39. Al MJ, van Hout BA, Michel BC, Rutten FF. Sample size calculation in economic evaluations. Health Econ 1998; 7: 327-335
40. Dent J, Talley NJ. Overview: Initial and long-term management of gastro-oesophageal reflux disease. Aliment Pharamcol Ther 2003; 17 (Suppl 1): 53-57